N
NTRA
Natera Inc
181.11
1.25+0.70%After Hours: 181.19 +0.08 +0.04%18:59 09/19 EDT
OPEN/PREV CLOSE180.00/179.86
TODAY RANGE178.46-181.85
VOL1.49M
MARKET CAP24.86B
52 WEEK RANGE117.27-183.00
AVG VOL (3M)1.30M
% TURNOVER1.08%
TURNOVER--
P/E (TTM)-95.2609
% RANGE1.88%
EPS(TTM)-1.9012
P/E(FORWARD)-92.4031
P/B19.88
BVPS9.11
DIVIDEND--
P/S14.16
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP23.96B
SHARES OUTSTANDING137.25M
NEXT EARNINGS11/10-11/14
FREE FLOAT132.29M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·5d ago
How a Legal Settlement and New Rival Test Could Influence Natera’s (NTRA) Competitive Strategy
Simply Wall St·09/09 15:49
A Fresh Look at Natera (NTRA) Valuation After Launch of ARCHER Phase III Bladder Cancer Trial
Simply Wall St·09/03 11:44
What Natera (NTRA)'s AI-Driven Clinical Trial Integration Means For Shareholders
Seeking Alpha·09/03 01:37
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2025 Update
TipRanks·09/02 21:00
Natera price target raised to $268 from $255 at RBC Capital
TipRanks·09/02 20:35
RBC Capital Reaffirms Their Buy Rating on Natera (NTRA)
Seeking Alpha·09/02 18:40
Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability
Simply Wall St·08/31 13:05
Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking
NASDAQ·08/29 22:09
Natera Updates On Patent Ruling In Litigation With NeoGenomics
Dow Jones·08/29 17:55
NeoGenomics' Patent Suit Win Provides Runway for Long-Term Growth -- Market Talk
Dow Jones·08/29 17:37
NeoGenomics' Patent Suit Win Is a Positive for the Stock -- Market Talk
Same Industry
Name/Symbol
Change%
Price